CVSA trades 27.6% above Wall Street's consensus target of $92.86.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CVSA achieves its forward estimates and maintains a stable P/E multiple of 15.9x. This scenario reflects the blended consensus of 3 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 8, 2026, Covista Inc. (CVSA) has a Wall Street consensus price target of $92.86, based on estimates from 3 covering analysts. With the stock currently trading at $110.32, this represents a potential downside of -27.6%. The company has a market capitalization of $3.67B.
Analyst price targets range from a low of $26.00 to a high of $170.00, representing a 155% spread in expectations. The median target of $84.00 differs from the mean, suggesting potential outlier estimates. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 3 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CVSA trades at a trailing P/E of 14.8x and forward P/E of 15.9x. The forward PEG ratio of 2.58 reflects a premium valuation. Analysts expect EPS to grow +15.2% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $151.97, with bear and bull scenarios of $95.74 and $200.24 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PRDOPerdoceo Education Corporation | $1.7B | $26.88 | $44.00 | +63.7% | Hold | 9.1x | 9 |
 LAURLaureate Education, Inc. | $4.7B | $33.59 | $39.75 | +18.3% | Buy | 15.9x | 11 |
 GHCGraham Holdings Company | $5.3B | $1212.02 | — | — | — | 16.4x | — |
 STRAStrategic Education, Inc. | $1.2B | $52.20 | $85.50 | +63.8% | Hold | 7.2x | 18 |
 UTIUniversal Technical Institute, Inc. | $1.1B | $19.93 | $38.33 | +92.3% | Buy | 33.0x | 11 |
 CHGGChegg, Inc. | $68M | $0.61 | $30.42 | +4885.3% | Hold | — | 22 |
 COURCoursera, Inc. | $687M | $3.74 | $6.38 | +70.6% | Hold | 5.9x | 17 |
 LOPEGrand Canyon Education, Inc. | $3.1B | $117.69 | $160.67 | +36.5% | Buy | 11.5x | 19 |
 ARCOArcos Dorados Holdings Inc. | $1.5B | $6.98 | $11.02 | +57.9% | Buy | 8.8x | 12 |
 VRSKVerisk Analytics, Inc. | $26.6B | $204.59 | $222.86 | +8.9% | Hold | 26.5x | 25 |
Quick answers to the most common questions about buying CVSA stock.
CVSA's consensus price target is $92.86, -27.6% below the current price of $110.32. The 3 analysts tracking CVSA see downside risk at present valuations.
CVSA has a consensus rating of "Buy" based on 3 Wall Street analysts. The rating breakdown is predominantly bullish, with 3 Buy/Strong Buy ratings. The consensus 12-month price target of $92.86 implies -27.6% downside from current levels.
With a forward P/E of 15.9181x, CVSA trades at a relatively low valuation. The consensus target of $92.86 implies -27.6% move, suggesting the market may be pricing in risks.
The most bullish Wall Street analyst has a price target of $170 for CVSA, while the most conservative target is $26. The consensus of $92.86 represents the median expectation. Our quantitative valuation model projects a bull case target of $200 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CVSA is lightly followed, with 3 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 3 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CVSA stock forecast based on 3 Wall Street analysts shows a consensus price target of $92.86, with estimates ranging from $26 (bear case) to $170 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $152, with bear/bull scenarios of $96/$200.
Our quantitative valuation model calculates CVSA's fair value at $152 (base case), with a bear case of $96 and bull case of $200. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
CVSA trades at a forward P/E ratio of 15.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 14.8x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on CVSA, with 0 Sell ratings and a price target of $92.86 (-27.6% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CVSA analyst price targets range from $26 to $170, a 155% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $92.86 consensus represents the middle ground. Our model's $96-$200 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.